Susan Frederick
Family · Beulaville, NCNPI 1043238587
Payments from drug & device makers
Across 217 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$471
- Pfizer$420
- Abbott$379
- GSK$313
- Amgen$259
- Boehringer Ingelheim$193
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,62392%
- Other$3258%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 31 | $471 |
| Pfizer | 24 | $420 |
| Abbott | 5 | $379 |
| GSK | 20 | $313 |
| Amgen | 16 | $259 |
| Boehringer Ingelheim | 12 | $193 |
| Novo Nordisk | 12 | $189 |
| AbbVie | 9 | $176 |
| E.r. Squibb & Sons, L.L.C. | 10 | $166 |
| Ardelyx, Inc. | 8 | $150 |
| Dexcom, Inc. | 8 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $114 |
| Sanofi-aventis U.S. LLC | 6 | $95 |
| Novartis | 5 | $89 |
| AstraZeneca | 5 | $82 |
| Merck | 4 | $75 |
| Bayer | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Currax Pharmaceuticals LLC | 5 | $70 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| Johnson & Johnson | 3 | $49 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $26 |
| Medtronic | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,947 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $63,056 |
| EliquisApixaban | 76 | $49,224 |
| MounjaroTirzepatide | 35 | $42,161 |
| JardianceEmpagliflozin | 35 | $35,590 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $31,142 |
| TrulicityDulaglutide | 16 | $18,451 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $16,197 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $14,713 |
| JanuviaSitagliptin Phosphate | 20 | $10,680 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $9,255 |
| SavellaMilnacipran Hcl | 15 | $6,464 |
| SynthroidLevothyroxine Sodium | 97 | $5,869 |
| XareltoRivaroxaban | 11 | $5,732 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $4,839 |
| Levothyroxine Sodium | 256 | $3,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $189 | $63,05660 claims |
| Lilly USA, LLCMounjaro, Trulicity | $471 | $60,61351 claims |
| PfizerEliquis, Premarin | $420 | $51,62689 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $193 | $40,42954 claims |
| GSKTrelegy Ellipta | $313 | $31,14250 claims |
| MerckJanumet Xr, Januvia | $75 | $25,39437 claims |
| AbbVieSavella, Synthroid | $176 | $12,333112 claims |
| Johnson & JohnsonXarelto | $49 | $5,73211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Beulaville
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.